Home > LILACS - Literatura Latinoamericana y del Caribe de Ciencias de la Salud > Search result

Results: 3

The effects of favipiravir on hematological parameters of covıd-19 patients

Yaylaci, Selçuk; Dheir, Hamad; Şenocak, Didar; Genc, Ahmed Bilal; Kocayigit, Havva; Çekiç, Deniz; Varim, Ceyhun; Aydın, Abdülkadir; Koroglu, Mehmet; Karabay, Oğuz.
Rev Assoc Med Bras (1992); 66 (Suppl 2), 2020
SUMMARY INTRODUCTION This study aims to evaluate changes in hematological parameters after the follow-up of patients who received treatment with favipiravir due to COVID-19 infections. METHODS Sixty-two cases receiving favipiravir treatment for at least five days due to COVID-19 infection were evalua...
Amidas/uso terapéutico, Betacoronavirus, Recuento de Linfocito CD4, Infecciones por Coronavirus, Infecciones por Coronavirus/tratamiento farmacológico, Infecciones por Coronavirus/epidemiología, Hemoglobinas/análisis, Recuento de Leucocitos, Persona de Mediana Edad, Pandemias, Recuento de Plaquetas, Neumonía Viral/tratamiento farmacológico, Neumonía Viral/epidemiología, Pirazinas/uso terapéutico, Estudios Retrospectivos
Fulltext

Beneficial effects of Oltipraz, nuclear factor - erythroid - 2 - related factor 2 (Nrf2), on renal damage in unilateral ureteral obstruction rat model

Polat, Emre Can; Besiroglu, Huseyin; Ozcan, Levent; Otunctemur, Alper; Eruyar, Ahmet Tugrul; Somay, Adnan; Ozbay, Nurver; Cekmen, Mustafa; Eraldemir, Ceyla; Ozbek, Emin.
Int. braz. j. urol; 44 (6), 2018
ABSTRACT Introduction: We investigated whether Oltipraz (OPZ) attenuated renal fibrosis in a unilateral ureteral obstruction (UUO) rat model. Materials and Methods: We randomly divided 32 rats into four groups, each consisting of eight animals as follows: Rats in group 1 underwent a sham operation and ...
Cadherinas/sangre, Modelos Animales de Enfermedad, Fibrosis/tratamiento farmacológico, Fibrosis/etiología, Hidroxiprolina/sangre, Inmunohistoquímica, Enfermedades Renales/tratamiento farmacológico, Enfermedades Renales/etiología, Enfermedades Renales/patología, Factor 2 Relacionado con NF-E2/uso terapéutico, Óxido Nítrico/sangre, Pirazinas/uso terapéutico, Ratas Wistar, Tionas, Tiofenos, Factor de Crecimiento Transformador beta1/sangre, Obstrucción Ureteral/complicaciones, Obstrucción Ureteral/tratamiento farmacológico, Obstrucción Ureteral/patología
Fulltext

Tratamiento da hiperlipidemia primária com ácido 5-metil-pirazina-2-carbocilico (acipimox)
Treatment of primary hyperlipidemia with 5-methylpyrazinecarboxylic acid (acipimox)

Quintäo, Eder Carlos da Rocha; Castilho, Lúcia N. de.
Arq. bras. cardiol; 44 (1), 1985
Após período controle de 2 meses, 14 pacientes hiperlipidêmicos foram tratados com acipimox (geralmente 750 mg/dia) durante aproximadamente 12 meses. Ocorreu reduçäo média de colesterolemia de 17%, sem que diminuisse significantemente a trigliceridemia, exceto nos casos de hipertrigliceridemia acim...
Hiperlipidemias/tratamiento farmacológico, Pirazinas/uso terapéutico, Colesterol/sangre, Triglicéridos/sangre
Fulltext